A BILL 
To require any COVID–19 drug developed in whole or in 
part with Federal support to be affordable and accessible 
by prohibiting monopolies and price gouging, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pandemic Treatment 
4
Access and Affordability Act of 2021’’. 
5
00:32 Feb 20, 2021
H597
2 
•HR 597 IH
SEC. 2. REQUIREMENTS FOR LICENSING OF NEW COVID–19 
1
TREATMENT 
AND 
PREVENTION 
TECH-
2
NOLOGIES TO MEET DOMESTIC AND GLOBAL 
3
DEMAND. 
4
(a) NONEXCLUSIVE LICENSE REQUIRED.—Any cov-
5
ered license granted by the Federal Government shall be 
6
an open, nonexclusive license. 
7
(b) 
CONTRACTOR, 
ASSIGNEE, 
EXCLUSIVE
LI-
8
CENSEE.—Notwithstanding any other provision of law, 
9
any contractor, assignee, or exclusive licensee to an inven-
10
tion developed in whole or in part in work performed 
11
under a covered transaction shall grant an open, non-ex-
12
clusive license. If any such contractor, assignee, or exclu-
13
sive licensee refuses to grant such license, the Federal gov-
14
ernment shall grant the license. 
15
(c) REASONABLE ROYALTY.— 
16
(1) IN GENERAL.—Except as provided in para-
17
graph (4), an entity that accepts an open, nonexclu-
18
sive license under this section shall pay a reasonable 
19
royalty with respect to sales within the United 
20
States to— 
21
(A) the holder of a patent that claims the 
22
COVID–19 related invention; or 
23
(B) to the holder of an application ap-
24
proved under section 505 of the Federal Food, 
25
Drug, and Cosmetic Act (21 U.S.C. 355) or 
26
00:32 Feb 20, 2021
H597
3 
•HR 597 IH
section 351 of the Public Health Service Act 
1
(42 U.S.C. 262) for which any FDA-granted 
2
exclusivity with respect to a drug related to 
3
such invention that was terminated under this 
4
section. 
5
(2) ROYALTY.—The reasonable royalty de-
6
scribed under paragraph (1) shall be a percentage of 
7
sales of the entity paying the royalty, where the per-
8
centage rate is no higher than the average royalty 
9
rate estimated from the data provided by the Inter-
10
nal Revenue Service for pharmaceutical manufac-
11
turer Federal income tax returns. 
12
(3) REQUIREMENTS.— 
13
(A) IN GENERAL.—The royalty described 
14
under paragraph (2) shall be subject to the ap-
15
plicable royalty rate requirements of section 
16
319B of the Public Health Service Act, as 
17
added by section 5 of this Act. 
18
(B) MULTIPLE
AFFECTED
PARTIES.—In 
19
the case of more than one recipient of a royalty, 
20
the royalty shall be divided among each such re-
21
cipient (including any manufacturer) in a man-
22
ner agreed upon by the manufacturer and other 
23
recipients, or, in the absence of such an agree-
24
00:32 Feb 20, 2021
H597
4 
•HR 597 IH
ment, in a manner the Secretary determines to 
1
be appropriate. 
2
(4) EXCEPTION FOR GOVERNMENT-OWNED IN-
3
VENTIONS.—An entity that accepts an open, non-
4
exclusive license for a federally owned invention de-
5
scribed under section 207 of title 35, United States 
6
Code, is not required to pay a royalty under this sec-
7
tion. 
8
(d) DEFINITIONS.—In this section: 
9
(1) COVERED LICENSE.—The term ‘‘covered li-
10
cense’’ means a license that allows a licensee to 
11
make, use, offer to sell, or sell, export, or import 
12
into the United States or any other country or terri-
13
tory a COVID–19 related invention pursuant to— 
14
(A) section 207 of title 35, United States 
15
Code; and 
16
(B) section 12 of the Stevenson-Wydler 
17
Technology Innovation Act of 1980 (15 U.S.C. 
18
3710a). 
19
(2) COVERED TRANSACTION.—The term ‘‘cov-
20
ered transaction’’ means any contract, funding 
21
agreement, license, other transaction, or other ar-
22
rangement entered into between a party and the 
23
Federal Government on or after the date of enact-
24
00:32 Feb 20, 2021
H597
5 
•HR 597 IH
ment of this Act with respect to research and devel-
1
opment regarding a drug that— 
2
(A) is intended or anticipated to be used to 
3
diagnose, mitigate, prevent, or treat COVID– 
4
19; and 
5
(B) consists of— 
6
(i) a licensing agreement pursuant to 
7
section 207 of title 35, United States 
8
Code; 
9
(ii) a cooperative research and devel-
10
opment agreement and licensing agreement 
11
pursuant to section 12 of the Stevenson- 
12
Wydler Technology Innovation Act of 1980 
13
(15 U.S.C. 3710a); 
14
(iii) a funding agreement, as defined 
15
under section 201 of title 35, United 
16
States Code; or 
17
(iv) any other transaction entered into 
18
pursuant to— 
19
(I) section 319L, 421, or 480 of 
20
the Public Health Service Act (42 
21
U.S.C. 247d–7e, 285b–3, 287a); 
22
(II) section 105 of the National 
23
Institutes of Health Reform Act of 
24
2006 (42 U.S.C. 284n); or 
25
00:32 Feb 20, 2021
H597
6 
•HR 597 IH
(III) section 2371 of title 10, 
1
United States Code. 
2
(3) COVID–19 
RELATED
INVENTION.—The 
3
term ‘‘COVID–19 related invention’’ means any in-
4
vention that claims a drug that is manufactured, 
5
used, designed, developed, modified, licensed, or pro-
6
cured to diagnose, mitigate, prevent, treat, or cure 
7
COVID–19; a use of such drug; a form of such 
8
drug; a method of use of such drug; or a method of 
9
manufacturing such drug. 
10
(4) FDA-GRANTED
EXCLUSIVITY.—The term 
11
‘‘FDA-granted exclusivity’’ means prohibitions on 
12
the submission or approval of drug applications 
13
granted under any of the following: 
14
(A) Clauses (ii) through (v) of section 
15
505(c)(3)(E) of the Federal Food, Drug, and 
16
Cosmetic Act (21 U.S.C. 355(c)(3)(E)). 
17
(B) Subsection (j)(5)(B)(iv) or clause (ii), 
18
(iii), or (iv) of subsection (j)(5)(F) of such Act 
19
(21 U.S.C. 355(c)(3)(E)). 
20
(C) Section 505A of such Act (21 U.S.C. 
21
355a). 
22
(D) Section 505E of such Act (21 U.S.C. 
23
355f). 
24
00:32 Feb 20, 2021
H597
7 
•HR 597 IH
(E) Section 527 of such Act (21 U.S.C. 
1
360cc). 
2
(F) Section 351(k)(7) of this Act (42 
3
U.S.C. 262(k)(7)). 
4
(G) Any other provision of law that pro-
5
vides for marketing or data exclusivity (or ex-
6
tension of exclusivity) with respect to a drug. 
7
(5) OPEN, NONEXCLUSIVE LICENSE.—The term 
8
‘‘open, nonexclusive license’’ means a license that al-
9
lows a qualified licensee, subject to the provisions of 
10
the Federal Food, Drug, and Cosmetic Act (21 
11
U.S.C. 301 et seq.) and the Public Health Service 
12
Act (42 U.S.C. 201 et seq.)— 
13
(A) to make, use, offer to sell, sell, export, 
14
or import into the United States and any other 
15
country and territory an invention; 
16
(B) to reference or rely upon earlier-sub-
17
mitted regulatory test data or the earlier grant 
18
of marketing approval of a treatment or vaccine 
19
related to such invention; and 
20
(C) to access and use otherwise confiden-
21
tial know-how relating to the manufacture of 
22
such invention. 
23
00:32 Feb 20, 2021
H597
8 
•HR 597 IH
SEC. 3. REQUIREMENTS FOR REASONABLE PRICING OF 
1
FEDERALLY SUPPORTED COVID–19 DRUGS. 
2
(a) REASONABLE PRICING REQUIREMENTS.—Any 
3
covered transaction shall include terms and conditions re-
4
quiring that the pricing of the drug by the party referred 
5
to in subsection (b)(1) be fair and reasonable, and facili-
6
tate global access, taking into consideration— 
7
(1) the impact of the price on access to the 
8
drug in the United States, taking into consideration 
9
racial disparities in COVID–19 cases and fatalities 
10
and other socioeconomic disparities; 
11
(2) the impact of the price on health program 
12
spending and budgets in the United States; 
13
(3) the risk adjusted value of Federal subsidies 
14
and investments related to the drug; 
15
(4) the costs associated with development and 
16
manufacturing of the drug; 
17
(5) the size of the affected patient population in 
18
the United States and globally; and 
19
(6) the therapeutic efficacy of the drug. 
20
(b) DEFINITIONS.—In this section: 
21
(1) COVERED TRANSACTION.—The term ‘‘cov-
22
ered transaction’’ has the meaning given to such 
23
term in section 2. 
24
00:32 Feb 20, 2021
H597
9 
•HR 597 IH
(2) DRUG.—The term ‘‘drug’’ has the meaning 
1
given to such term in section 201 of the Federal 
2
Food, Drug, and Cosmetic Act (21 U.S.C. 321). 
3
SEC. 4. REPORTING ON THE EXPENDITURES OF MANUFAC-
4
TURERS WITH RESPECT TO COVID–19 DRUGS. 
5
(a) COVERED DRUG.—For purposes of this section, 
6
the term ‘‘covered drug’’ means a drug that is intended 
7
or anticipated to be used to diagnose, mitigate, prevent, 
8
or treat COVID–19. 
9
(b) REPORTING REQUIRED.—The manufacturer of a 
10
covered drug shall submit a report described in subsection 
11
(c) to the Secretary upon— 
12
(1) the submission of an application for ap-
13
proval of the drug under subsection (b) or (j) of sec-
14
tion 505 of the Federal Food, Drug, and Cosmetic 
15
Act (21 U.S.C. 355); 
16
(2) investigational use of the drug under section 
17
505(i) of the Federal Food, Drug, and Cosmetic Act 
18
(21 U.S.C. 355(i)) or section 351 of the Public 
19
Health Service Act (42 U.S.C. 262); 
20
(3) the submission of an application for licens-
21
ing the drug under subsection (a) or (k) of section 
22
351 of the Public Health Service Act (42 U.S.C. 
23
262); 
24
00:32 Feb 20, 2021
H597
10 
•HR 597 IH
(4) the issuance of an authorization for emer-
1
gency use of the drug under section 564 of the Fed-
2
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
3
360bbb–3); or 
4
(5) the marketing of the drug. 
5
(c) CONTENTS.—A report under subsection (a), con-
6
sistent with the standard for disclosures described in sec-
7
tion 213.3(d) of title 12, Code of Federal Regulations (as 
8
in effect on the date of enactment of this Act), shall ad-
9
dress the expenditures of the manufacturer with respect 
10
to the covered drug and include, at a minimum— 
11
(1) the sponsor or sponsors of the covered drug; 
12
(2) the current wholesale acquisition cost of the 
13
covered drug when applicable; 
14
(3) the total expenditures of the manufacturer, 
15
specified by individual costs, on— 
16
(A) materials and manufacturing for the 
17
covered drug; and 
18
(B) acquiring patents and licensing for the 
19
covered drug; 
20
(4) the total amount and percentage of research 
21
and development expenditures for the covered drug 
22
that was derived from Federal funds; 
23
00:32 Feb 20, 2021
H597
11 
•HR 597 IH
(5) the total amount of any Federal benefits re-
1
ceived by the manufacturer with respect to the cov-
2
ered drug, including— 
3
(A) the specific amounts and periods of 
4
impact for each such benefit; 
5
(B) the specific value of any tax credits, 
6
including benefits from patient assistance pro-
7
grams and donated samples; 
8
(C) clinical and preclinical investments; 
9
(D) any Federal benefit toward manufac-
10
turing costs, including building or retrofitting 
11
facilities; 
12
(E) Federal grants, including from the Na-
13
tional Institutes of Health, the Centers for Dis-
14
ease Control and Prevention, the Department of 
15
Defense, the Department of Energy, or other 
16
Federal departments or agencies; 
17
(F) patent applications that benefitted 
18
from such grants; 
19
(G) patent extensions; 
20
(H) exclusivity periods; and 
21
(I) waivers of fees; 
22
(6) the total expenditures of the manufacturer 
23
on research and development, itemized by basic and 
24
preclinical research and by clinical research, re-
25
00:32 Feb 20, 2021
H597
12 
•HR 597 IH
ported separately for each clinical trial, for the cov-
1
ered drug to demonstrate that the covered drug 
2
meets applicable statutory standards for approval 
3
under section 505 of the Federal Food, Drug, and 
4
Cosmetic Act (21 U.S.C. 355), licensure under sec-
5
tion 351 of the Public Health Service Act (42 
6
U.S.C. 262), an exemption for investigational use 
7
under section 505(i) of the Federal Food, Drug, or 
8
Cosmetic Act (21 U.S.C. 355(i)) or section 351 of 
9
the Public Health Service Act, or approval under 
10
section 564 of the Federal Food, Drug, and Cos-
11
metic Act (21 U.S.C. 360bbb–3), as applicable; 
12
(7) the total expenditures of the manufacturer 
13
on pursuing new or expanded indications or dosage 
14
changes for the covered drug under section 505 of 
15
the Federal Food, Drug, and Cosmetic Act (21 
16
U.S.C. 355) or section 351 of the Public Health 
17
Service Act (42 U.S.C. 262); 
18
(8) the total expenditures of the manufacturer 
19
on carrying out postmarket requirements related to 
20
such drug, including under section 505(o)(3) of the 
21
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
22
355–1); 
23
00:32 Feb 20, 2021
H597
13 
•HR 597 IH
(9) the specific expenditures associated with 
1
marketing and advertising costs for the covered 
2
drug; 
3
(10) any anticipated royalty fees from licensing 
4
to other manufacturers; and 
5
(11) with respect to the manufacturer— 
6
(A) all stock-based performance metrics 
7
used by the manufacturer to determine execu-
8
tive compensation over the preceding 12 
9
months; and 
10
(B) any additional information the manu-
11
facturer chooses to provide related to drug pric-
12
ing decisions. 
13
(d) CIVIL MONETARY PENALTIES.— 
14
(1) FAILURE TO SUBMIT.—Any manufacturer 
15
of a covered drug that fails to submit a report as 
16
required by this section, following notification by the 
17
Secretary to the manufacturer that the manufac-
18
turer is not in compliance with this section, shall be 
19
subject to a civil monetary penalty of $100,000 for 
20
each day on which the violation continues. 
21
(2) FALSE INFORMATION.—Any manufacturer 
22
of a covered drug that knowingly provides false in-
23
formation in a report under this section is subject to 
24
00:32 Feb 20, 2021
H597
14 
•HR 597 IH
a civil monetary penalty in an amount not to exceed 
1
$100,000 for each item of false information. 
2
(e) PUBLIC POSTING.— 
3
(1) IN GENERAL.—Subject to paragraph (3), 
4
the Secretary shall post each report submitted under 
5
subsection (b) on the public website of the Depart-
6
ment of Health and Human Services no later than 
7
30 days after the submission of the report. 
8
(2) FORMAT.—The Secretary shall ensure that 
9
such reports are— 
10
(A) user-friendly to the public; and 
11
(B) written in plain language that con-
12
sumers can readily understand. 
13
(3) PROTECTED
INFORMATION.—Nothing in 
14
this section shall be construed to authorize the pub-
15
lic disclosure of information submitted by a manu-
16
facturer that is prohibited from disclosure by appli-
17
cable laws concerning the protection of trade secrets, 
18
commercial information, and other information cov-
19
ered under such laws. 
20
(f) DEFINITION.—In this section, the term ‘‘drug’’ 
21
has the meaning given to such term in section 201 of the 
22
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321). 
23
00:32 Feb 20, 2021
H597
15 
•HR 597 IH
SEC. 5. PRICING REQUIREMENTS FOR EXISTING TREAT-
1
MENTS AND VACCINES IN A PUBLIC HEALTH 
2
EMERGENCY. 
3
Title III of the Public Health Service Act is amended 
4
by inserting after section 319A (42 U.S.C. 247d–1a) the 
5
following new section: 
6
‘‘SEC. 319B. PRICING REQUIREMENTS FOR TREATMENTS 
7
AND VACCINES IN A PUBLIC HEALTH EMER-
8
GENCY. 
9
‘‘(a) DEFINITIONS.—For purposes of this section: 
10
‘‘(1) The term ‘covered drug’ means a drug (in-
11
cluding any vaccine) used to diagnose, mitigate, pre-
12
vent, or treat a disease or disorder with respect to 
13
which there is or was in effect a declaration of a 
14
public health emergency under section 319. 
15
‘‘(2) The term ‘covered period’ means the pe-
16
riod ending if and when the circumstances which led 
17
to the public health emergency cease to exist and are 
18
unlikely to recur. 
19
‘‘(3) The term ‘FDA-granted exclusivity’ means 
20
prohibitions on the submission or approval of drug 
21
applications granted under any of the following: 
22
‘‘(A) Clauses (ii) through (v) of section 
23
505(c)(3)(E) of the Federal Food, Drug, and 
24
Cosmetic Act. 
25
00:32 Feb 20, 2021
H597
16 
•HR 597 IH
‘‘(B) Subsection (j)(5)(B)(iv) or clause (ii), 
1
(iii), or (iv) of subsection (j)(5)(F) of such Act. 
2
‘‘(C) Section 505A of such Act. 
3
‘‘(D) Section 505E of such Act. 
4
‘‘(E) Section 527 of such Act. 
5
‘‘(F) Section 351(k)(7) of this Act. 
6
‘‘(G) Any other provision of law that pro-
7
vides for marketing or data exclusivity (or ex-
8
tension of exclusivity) with respect to a drug. 
9
‘‘(4) The term ‘wholesale acquisition cost’ has 
10
the 
meaning 
given 
that 
term 
in 
section 
11
1847A(c)(6)(B) of the Social Security Act. 
12
‘‘(b) DETERMINATION OF EXCESSIVE PRICE.—Dur-
13
ing any covered period with respect to a covered drug, the 
14
Secretary shall determine that the price of a covered drug 
15
is excessive if the wholesale acquisition cost (or a more 
16
relevant measure of price) of the covered drug is not fair 
17
and reasonable, or does not facilitate global access, taking 
18
into consideration— 
19
‘‘(1) the impact of the price on access to the 
20
covered drug in the United States, taking into con-
21
sideration racial disparities and other socioeconomic 
22
disparities; 
23
‘‘(2) the impact of the price on health program 
24
spending and budgets in the United States; 
25
00:32 Feb 20, 2021
H597
17 
•HR 597 IH
‘‘(3) the risk adjusted value of Federal sub-
1
sidies and investments related to the covered drug; 
2
‘‘(4) the costs associated with development and 
3
manufacturing of the covered drug; 
4
‘‘(5) the size of the affected patient population 
5
in the United States and globally; and 
6
‘‘(6) the therapeutic efficacy of the covered 
7
drug. 
8
‘‘(c) EXCESSIVE PRICING REMEDY.—If the Secretary 
9
determines pursuant to subsection (b) that the price of 
10
a covered drug is excessive, the Secretary— 
11
‘‘(1) shall waive or void any FDA-granted 
12
exclusivities with respect to the covered drug, effec-
13
tive on the date that the excessive price determina-
14
tion is made; and 
15
‘‘(2) shall grant open, nonexclusive licenses al-
16
lowing any person to make, use, offer to sell, or sell, 
17
or import into the United States such drug, and to 
18
rely upon the regulatory test data of such drug, and 
19
to access and use otherwise confidential information, 
20
including know-how, related to the manufacture of 
21
such drug in accordance with subsection (d). 
22
‘‘(d) REASONABLE ROYALTY.— 
23
‘‘(1) IN
GENERAL.—An entity accepting an 
24
open, nonexclusive license under subsection (c)(2) 
25
00:32 Feb 20, 2021
H597
18 
•HR 597 IH
shall pay a reasonable royalty with respect to sales 
1
within the United States to the holder of a patent 
2
that claims the covered drug or that claims a use of 
3
the covered drug or to the holder of an application 
4
approved under section 505 of the Federal Food, 
5
Drug, and Cosmetic Act or section 351 of the Public 
6
Health Service Act for which any FDA-granted ex-
7
clusivity with respect to the covered drug was termi-
8
nated under subsection (c)(1). 
9
‘‘(2) ROYALTY RATE.—Such royalty rate shall 
10
be— 
11
‘‘(A) a percentage of sales, where the per-
12
centage rate is no higher than the average roy-
13
alty rate estimated from the data provided by 
14
the Internal Revenue Service for pharma-
15
ceutical manufacturer Federal income tax re-
16
turns; or 
17
‘‘(B) an amount as determined by the Sec-
18
retary, taking into account— 
19
‘‘(i) the therapeutic efficacy of the 
20
covered drug; 
21
‘‘(ii) the size of the affected patient 
22
population in the United States and glob-
23
ally; 
24
00:32 Feb 20, 2021
H597
19 
•HR 597 IH
‘‘(iii) the risk adjusted value of Fed-
1
eral subsidies and investments related to 
2
the covered; 
3
‘‘(iv) the extent to which the manufac-
4
turer of the covered drug has recovered 
5
risk adjusted investments related to the 
6
covered drug, including the investments re-
7
lated to the invention, regulatory test data, 
8
and any other relevant research and devel-
9
opment costs; and 
10
‘‘(v) any other information the Sec-
11
retary determines appropriate. 
12
‘‘(3) SALES
WITHIN
OTHER
COUNTRIES.—An 
13
entity accepting an open, nonexclusive license under 
14
subsection (c)(2) shall pay a reasonable royalty with 
15
respect to sales within other countries based on the 
16
royalty rate paid in the United States times the 
17
ratio between that country’s gross domestic product 
18
per capita divided by the United States gross domes-
19
tic product per capita in the last year such data was 
20
available for both countries, but such royalty shall 
21
only be due if there are granted patents or data ex-
22
clusivity rights in that country at the time of sale. 
23
‘‘(e) REQUIREMENTS.— 
24
00:32 Feb 20, 2021
H597
20 
•HR 597 IH
‘‘(1) IN GENERAL.—A royalty rate under sub-
1
section (d) shall be consistent with making the cov-
2
ered drug available to purchasers, including govern-
3
mental and nongovernmental purchasers and individ-
4
uals, at prices that are affordable and reasonable. 
5
Under no condition shall a royalty be set at a rate 
6
that would cause a covered drug for which an open, 
7
nonexclusive license was issued under subsection (c) 
8
to be sold at an excessive price, as determined under 
9
subsection (b). 
10
‘‘(2) MULTIPLE
AFFECTED
PARTIES.—In the 
11
case that there is one or more holders or investors 
12
in the patented inventions related to the covered 
13
drug, the royalty rate shall be divided among the 
14
holders or investors (including such manufacturer) 
15
in a manner agreed upon by the manufacturer and 
16
other holders or investors, or, in the absence of such 
17
an agreement, in a manner the Secretary determines 
18
to be appropriate. 
19
‘‘(3) PRICE.—An entity accepting an open, non-
20
exclusive license under subsection (c)(2) shall sell 
21
the covered drug at a price not higher than the ex-
22
cessive price determined for the covered drug under 
23
subsection (b). 
24
00:32 Feb 20, 2021
H597
21 
•HR 597 IH
‘‘(f) CLARIFICATION.—An open, nonexclusive license 
1
under subsection (c)(2) shall be liable, subject to adequate 
2
protection of the legitimate interests of any party utilizing 
3
the license, to be terminated only if the circumstances 
4
which led to the granting of the open, nonexclusive license 
5
cease to exist and are unlikely to recur. The Secretary may 
6
review, upon request, the continued existence of these cir-
7
cumstances.’’. 
8
Æ 
00:32 Feb 20, 2021
H597
